Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Hormonal contraceptive may up risk of breast cancer

Tristan Manalac
23 Dec 2017
Kratom capsules being sold in the United States. Photo credit: AP/New York Post

Contemporary hormonal contraceptives appear to increase the risk of breast cancer, particularly in those with long durations of exposure, a recent study from Denmark has shown.

However, while the current study did not take into consideration additional breast cancer cases after the discontinuation of hormonal contraception, the absolute increase in risk is low, researchers said.

In 1,797,932 females without cancer or venous thromboembolism, there were 11,517 incident cases of breast cancer over a mean follow-up of 10.9±5.8 years. The current or recent use of any hormonal contraception significantly elevated the risk of breast cancer compared with never use (relative risk [RR], 1.20; 95 percent CI, 1.14–1.26; p=0.002). [N Engl J Med 2017;377:2228-2239]

Moreover, the duration of hormonal contraception had a significant effect on the risk of breast cancer (p=0.002), such that those with <1 year of use have lower risks (RR, 1.09; 0.96–1.23) than those with >10 years of use (RR, 1.38; 1.26–1.51).

Further stratification showed that the risk of breast cancer was only elevated in females with prolonged use (≥5 years), and that the increased risk persisted for at least 5 years after discontinuation of contraception (RR, 1.30; 1.06–1.58). In contrast, <5 years of exposure had no apparent impact on breast cancer risk.

“Our results suggest the rapid disappearance of excess risk of breast cancer after discontinuation of use among women who have used hormonal contraceptives for short periods, whereas the risk among women who have used these contraceptives for longer periods may persist for at least 5 years after discontinuation,” researchers said.

The age-standardized incidence rates of breast cancer for those with and without current or recent exposure to hormonal contraception were 55 and 58 events per 100,000 person-years, resulting in an age-adjusted risk difference of 3.

Despite the statistical link between the use of hormonal contraception in the past 6 months and the elevated risk of breast cancer, researchers said that, practically, the absolute increase in breast cancer cases as a result of hormonal contraception is low.

“[A]pproximately one extra breast cancer was diagnosed for every 7,690 women using hormonal contraception for 1 year… This risk should be weighed against important benefits of hormonal contraceptives such as good contraceptive efficacy and reduced risks of ovarian, endometrial, and perhaps colorectal cancer,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.